FierceBiotech 4 févr. 2026 Lilly drops 3 pipeline drugs, including gene therapy, from $1B Prevail buyout
BioPharma Dive 4 févr. 2026 Lilly soars again as fast-selling weight loss drugs top Wall Street projections
PharmaVoice 29 janv. 2026 Eli Lilly, BioAge chase NLRP3 inhibitors with ‘pipeline in a pill’ potential
FierceBiotech 29 janv. 2026 Repertoire adds Lilly to range of Big Pharma partners in autoimmune deal worth up to $2.69B
BioPharma Dive 28 janv. 2026 Lilly bets on Seamless, delving further into genetic medicine for hearing loss
FierceBiotech 28 janv. 2026 Lilly pens $1.1B pact with German biotech to work on gene editing med for hearing loss
Endpoints News 27 janv. 2026 CMS picks Lilly’s Trulicity, Gilead's Biktarvy for third round of Medicare negotiations
Endpoints News 23 janv. 2026 Former FDA deputies land at Lilly, AbbVie; Italy's Angelini has a new CEO
BioPharma Dive 14 janv. 2026 Lilly, chasing Novo, expects second-quarter FDA decision on obesity pill
PharmaVoice 14 janv. 2026 Lilly, Novo test direct-to-employer approach that could cut out PBMs and lower costs
FierceBiotech 12 janv. 2026 JPM26, Day 1: Stock market titans Lilly, Nvidia expand team-up with AI co-innovation lab
FierceBiotech 12 janv. 2026 Lilly, Nvidia tag on partnership with new AI co-innovation lab, $1B investment